- Home
- RNA
as of 01-30-2026 3:38pm EST
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 10.9B | IPO Year: | 2020 |
| Target Price: | $69.26 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.51 - $72.74 | Next Earning Date: | 02-26-2026 |
| Revenue: | $20,868,000 | Revenue Growth: | 106.27% |
| Revenue Growth (this year): | 88.12% | Revenue Growth (next year): | 18.11% |
AI-Powered RNA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
President and CEO
Avg Cost/Share
$72.45
Shares
14,387
Total Value
$1,042,338.15
Owned After
277,000
Director
Avg Cost/Share
$72.45
Shares
1,758
Total Value
$127,367.10
Owned After
16,562
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$72.45
Shares
4,542
Total Value
$329,067.90
Owned After
62,025
Chief Scientific Officer
Avg Cost/Share
$72.45
Shares
6,534
Total Value
$473,388.30
Owned After
85,093
Chief Human Resources Officer
Avg Cost/Share
$72.45
Shares
2,929
Total Value
$212,206.05
Owned After
113,938
Chief Medical Officer
Avg Cost/Share
$72.45
Shares
4,895
Total Value
$354,642.75
Owned After
31,599
President and CEO
Avg Cost/Share
$72.23
Shares
8,576
Total Value
$619,444.48
Owned After
277,000
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$72.23
Shares
1,974
Total Value
$142,582.02
Owned After
62,025
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$72.23
Shares
2,373
Total Value
$171,401.79
Owned After
85,093
SEC Form 4
Chief Human Resources Officer
Avg Cost/Share
$72.23
Shares
1,965
Total Value
$141,931.95
Owned After
113,938
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Boyce Sarah | RNA | President and CEO | Jan 21, 2026 | Sell | $72.45 | 14,387 | $1,042,338.15 | 277,000 | |
| LEVIN ARTHUR A | RNA | Director | Jan 21, 2026 | Sell | $72.45 | 1,758 | $127,367.10 | 16,562 | |
| MacLean Michael F | RNA | Chief Financial Officer | Jan 21, 2026 | Sell | $72.45 | 4,542 | $329,067.90 | 62,025 | |
| Flanagan W. Michael | RNA | Chief Scientific Officer | Jan 21, 2026 | Sell | $72.45 | 6,534 | $473,388.30 | 85,093 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Jan 21, 2026 | Sell | $72.45 | 2,929 | $212,206.05 | 113,938 | |
| Hughes Steven George | RNA | Chief Medical Officer | Jan 21, 2026 | Sell | $72.45 | 4,895 | $354,642.75 | 31,599 | |
| Boyce Sarah | RNA | President and CEO | Jan 7, 2026 | Sell | $72.23 | 8,576 | $619,444.48 | 277,000 | |
| MacLean Michael F | RNA | Chief Financial Officer | Jan 7, 2026 | Sell | $72.23 | 1,974 | $142,582.02 | 62,025 | |
| Flanagan W. Michael | RNA | Chief Scientific Officer | Jan 7, 2026 | Sell | $72.23 | 2,373 | $171,401.79 | 85,093 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Jan 7, 2026 | Sell | $72.23 | 1,965 | $141,931.95 | 113,938 |
Compare RNA vs Leading Stocks
See how RNA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.